<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04304755</url>
  </required_header>
  <id_info>
    <org_study_id>2019/583</org_study_id>
    <nct_id>NCT04304755</nct_id>
  </id_info>
  <brief_title>Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD)</brief_title>
  <acronym>Z-AMD</acronym>
  <official_title>Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (The Z-AMD Study): a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A PHASE IIA CLINICAL TRIAL OF ZOLEDRONIC ACID AS ADJUVANT THERAPY TO STANDARD ANTI-VASCULAR
      ENDOTHELIAL GROWTH FACTOR (ANTI-VEGF) TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR
      DEGENERATION (AMD)
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of anti-VEGF intravitreal injections given after 48 weeks.</measure>
    <time_frame>After 48 weeks of treatment.</time_frame>
    <description>To assess the number of anti-VEGF injections needed during 48 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of anti-VEGF intravitreal injections given after 96 weeks.</measure>
    <time_frame>After 96 weeks of treatment.</time_frame>
    <description>To assess the number of anti-VEGF injections needed during 96 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in best-corrected visual acuity (BCVA) after 48 weeks.</measure>
    <time_frame>48 weeks</time_frame>
    <description>To assess the change in best-corrected visual acuity measured by logMAR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in best-corrected visual acuity (BCVA) after 96 weeks.</measure>
    <time_frame>96 weeks</time_frame>
    <description>To assess the change in best-corrected visual acuity measured by logMAR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a change in BCVA of 0.3 logMAR or more after 48 weeks.</measure>
    <time_frame>48 weeks</time_frame>
    <description>Number of patients with a change in BCVA of 0.3 logMAR or more after 48 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a change in BCVA of 0.3 logMAR or more after 96 weeks.</measure>
    <time_frame>96 weeks</time_frame>
    <description>Number of patients with a change in BCVA of 0.3 logMAR or more after 96 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients on extended anti-VEGF injection interval (&gt;4 weeks) after 48 weeks.</measure>
    <time_frame>48 weeks</time_frame>
    <description>Proportion of patients on extended anti-VEGF injection interval (&gt;4 weeks) after 48 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients on extended anti-VEGF injection interval (&gt;4 weeks) after 96 weeks.</measure>
    <time_frame>96 weeks</time_frame>
    <description>Proportion of patients on extended anti-VEGF injection interval (&gt;4 weeks) after 96 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients reaching the Maximum anti-VEGF injection interval of 12 weeks after 48 weeks.</measure>
    <time_frame>48 weeks</time_frame>
    <description>Proportion of patients reaching the Maximum anti-VEGF injection interval of 12 weeks after 48 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients reaching the Maximum anti-VEGF injection interval of 12 weeks after 96 weeks.</measure>
    <time_frame>96 weeks</time_frame>
    <description>Proportion of patients reaching the Maximum anti-VEGF injection interval of 12 weeks after 96 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in Central retinal thickness (CRT) after 48 weeks.</measure>
    <time_frame>48 weeks</time_frame>
    <description>Mean change from baseline in Central retinal thickness (CRT) after 48 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in Central retinal thickness (CRT) after 96 weeks.</measure>
    <time_frame>96 weeks</time_frame>
    <description>Mean change from baseline in Central retinal thickness (CRT) after 96 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with treatment-resistant AMD.</measure>
    <time_frame>48 weeks and 96 weeks</time_frame>
    <description>Proportion of patients with treatment-resistant AMD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ 5D score (ranging from 0-1; 0 designates &quot;perfect health&quot; and NEI-VFQ-25 score (ranging from 0 to 100 where 100 reflects best vision-specific health).</measure>
    <time_frame>Baseline, 48 weeks and 96 weeks</time_frame>
    <description>EQ 5D score (ranging from 0-1; 0 designates &quot;perfect health&quot; and NEI-VFQ-25 score (ranging from 0 to 100 where 100 reflects best vision-specific health).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients experiencing adverse events of special interest (ESI): osteonecrosis of the jaw or atypical femoral fracture, endophthalmitis or orbital, scleral, or serious intraocular inflammation (grade 4 aqueous cells/FLARE).</measure>
    <time_frame>48 weeks and 96 weeks</time_frame>
    <description>Proportion of patients experiencing adverse events of special interest (ESI): osteonecrosis of the jaw or atypical femoral fracture, endophthalmitis or orbital, scleral, or serious intraocular inflammation (grade 4 aqueous cells/FLARE).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Zoledronic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zoledronic acid 5 mg IV at baseline and after 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NaCl</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 ml 0.9% NaCl IV at baseline and after 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic Acid 4 MG in 5 ML Injection</intervention_name>
    <description>Zoledronic acid</description>
    <arm_group_label>Zoledronic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>NaCl 0.9%</description>
    <arm_group_label>NaCl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Active, treatment-naïve neovascular AMD in the study eye, intraretinal or subretinal fluid
        involving the fovea centre on optical coherence tomography (OCT), and evidence of choroidal
        neovascularization on fluorescein angiography (FA) and/or OCT angiography (OCT-A).

          1. Age ≥50 years

          2. Best-corrected visual acuity (BCVA) between 0.1 and 1.0 logMAR

          3. Menopausal for at least one year

          4. Subjects must give written informed consent before any study related procedures are
             performed

        Exclusion Criteria:

          1. Lesions comprising more than 50% blood or fibrosis involving the fovea centre

          2. Polypoidal choroidal vasculopathy (PCV) - indocyanine green (ICG) angiography is
             performed at the discretion of the investigator on clinical suspicion of PCV

          3. Presence of other ocular disease causing concurrent vision loss

          4. Presence of ocular disease making intravitreal treatment contraindicated (e.g. current
             ocular or periocular infection, active uveitis or uncontrolled glaucoma/intraocular
             pressure ≥ 25 mmHg)

          5. Systemic anti-vascular endothelial growth factor (anti-VEGF) or bisphosphonate
             treatment within one year preceding the initial study treatment

          6. Confirmed or suspected active malignancy

          7. Other factors (i.e. lack of cooperation) that, in the opinion of the investigator, can
             interfere with the study protocol

          8. Known or suspected hypersensitivity to any of the trial products

          9. Hypocalcemia (total Ca &lt; 2.15 mmol/L)

         10. Renal impairment (estimated ClCR &lt; 35 ml/min).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten C Moe, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Morten C Moe, MD, PhD</last_name>
    <phone>+47 23015166</phone>
    <email>mortmo@ous-hf.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Øystein K Jørstad, MD</last_name>
    <phone>+47 22118545</phone>
    <email>oeyjoe@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Spesialistsenteret Pilestredet Park</name>
      <address>
        <city>Oslo</city>
        <zip>0176</zip>
        <country>Norway</country>
      </address>
    </facility>
    <contact>
      <last_name>Erik F Eriksen, MD PhD</last_name>
      <phone>+47 22992700</phone>
      <email>efinkeriksen@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Erik F Eriksen, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo university hospital, Department of Ophthamology</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
    <contact>
      <last_name>Øystein K Jørstad, MD</last_name>
      <phone>+47 22118080</phone>
      <email>oeyjoe@ous-hf.no</email>
    </contact>
    <investigator>
      <last_name>Øystein K Jørstad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Morten Carstens Moe</investigator_full_name>
    <investigator_title>MD, Professor in Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

